AMAG AMAG Pharmaceuticals, Inc.

23.45
-0.75  -3.1%
Previous Close 24.20
Open 24.20
Price To book 0.88
Market Cap 802.20M
Shares 34,209,000
Volume 808,962
Short Ratio 6.88
Av. Daily Volume 1,292,270

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Hypoactive sexual desire disorder (HSDD)
Phase 3 trial to be completed estimated 1Q 2017. sNDA due mid 2017.
Feraheme
Adults with iron deficiency anemia (IDA)
PK data due 1Q 2017 with sNDA filing to follow in 2Q 2017.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. Is AMAG Pharmaceuticals (AMAG) A Good Value Pick?
  2. AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : January 11, 2017
  3. AMAG Pharma downgraded by Needham
  4. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  5. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  6. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  7. AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : January 10, 2017
  8. Why AMAG Pharmaceuticals, Inc. Is Falling Today
  9. New Strong Sell Stocks for January 9th
  10. AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and F
  11. AMAG Pharmaceuticals Provides Financial and Business Update
  12. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  13. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  14. AMAG Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
  15. Where Will AMAG Pharmaceuticals Be 1 Year From Now?
  16. AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
  17. AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors
  18. AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors
  19. AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research
  20. AMAG Pharma Up On Pre-Eclampsia Drug Potential; Stock On Four-Day Run